- Company Overview
- Management Team
- Board of Directors
- Scientific Advisors
- Corporate Mission
- Company History
You are here: Home » About Us » Board of Directors
Jan Egberts, M.D.
Chairman and independent Board member
Jan Egberts, M.D. has significant senior management experience in the venture capital, specialty pharmaceutical and medical device sectors. Most recently an industrialist-in residence and senior advisor for the Healthcare Investments group of private equity firm 3i, his many corporate management positions have included: chief executive officer and chairman of Novadel; chief operating officer of Dynogen; chairman of Molnlycke Healthcare Inc. and president of Molnlycke’s BARRIER Surgical division; vice president of worldwide business and market development as well as a global executive board member for Johnson & Johnson Medical; and executive director of marketing at Merck & Co. He received his M.D. from Erasmus University Medical School in the Netherlands and completed postgraduate clinical training at Harvard Medical School. He also earned a master’s degree in business administration from Stanford University.
Partner, VI Partners
Diego Braguglia joined VI Partners in January 2003 as a partner focusing on life-science and biotech investments. He brings to the firm more than 15 years of business experience in life sciences, medical devices and pharmaceuticals in Europe and the United States. Prior to his entry into the venture capital business, Braguglia held various senior management positions in the pharmaceutical and medical device sectors, as well as in biotech start-ups in Europe and the United States. Braguglia holds a master of science degree in microbiology from the Biocenter of the University of Basel and a Ph.D. in molecular and cellular biology from the Swiss Cancer Research Institute (ISREC) in Lausanne.
Michael Dormer has more than 30 years of experience in the medical device sector, with the majority of his career spent in progressively senior management positions at Johnson & Johnson and DePuy (acquired in 1998 by Johnson & Johnson). He most recently served as Johnson & Johnson’s Worldwide Chairman, Medical Devices and was a member of the company’s Executive Committee. An active voice in the industry, Dormer has also served on the Executive Committee of AdvaMed. He is currently the executive chairman of Neoss Ltd. and non-executive chairman of Jenavalve Inc. Dormer earned a bachelor’s degree in economics as well as a Master of Arts degree in economics and financial control from Lancaster University in the United Kingdom.
Endosense President and Chief Executive Officer
Jan Keltjens joined Endosense as president and chief executive officer in September 2011, bringing to the company two decades of global leadership experience in the medical device and technology sectors. Prior to Endosense, he served as chief executive officer of AngioDynamics Inc. (NASDAQ: ANGO) as well as CryoCath Technologies Inc., which was acquired by Medtronic under his leadership in 2008 (now Medtronic CryoCath). Jan has also held a number of senior leadership positions at Cordis, a Johnson & Johnson company and Unilever, with global responsibilities spanning sales, marketing, operations, finance, and research and development. Jan graduated from St. Thomas College in Venlo, The Netherlands, and earned a secondary degree in physics from the University of Eindhoven, The Netherlands.
Olivier Litzka, Ph.D.
Partner, Edmond de Rothschild Investment Partners (EdRIP)
Olivier Litzka has been a partner with Paris-based Edmond de Rothschild Investment Partners (EdRIP) since 2006. He invests primarily in European biotechnology and medtech companies as well as some investments in the United States. In addition to Endosense, he serves on the boards of Novexel, Noxxon Pharma, SuperSonic Imagine and JenaValve Technologies. Before joining EdRIP, Litzka spent six years with 3i’s life science venture capital practice, based first in Munich and then in Paris. In this position, he served on the boards of several portfolio companies and made a range of international investments. Before joining 3i in 2000, he worked as a strategy consultant with Mercer Management Consulting for several years, both in Munich and Paris. Litzka holds a Ph.D. in molecular microbiology from the Institut für Mikrobiologie at the University of Munich and did his scientific research work over several years in Munich and Oxford.
Claudio Nessi, Ph.D.
Claudio Nessi joined NeoMed in June 2001 and became a partner in 2004. He has been involved in the creation and financing of numerous companies in the health care field and has served on the board of directors of Axovan prior to its acquisition by Actelion. He is also currently a director of Kuros Biosurgery, Preglem, Creabilis and Endosense. Nessi has completed postdoctoral research work at the Max Planck Institute, Munich, and the University of Connecticut. He received his master’s degree in business administration from the Erasmus University, Rotterdam, and completed a Ph.D. in genetics at the University of Pavia, Italy. Nessi is the author of several scientific articles in the fields of microbiology and protein chemistry.
Patrick Van Beneden
Executive Vice President – Life Sciences, Gimv
Patrick Van Beneden has worked at Gimv since 1985 and heads up the firm’s Life Sciences business unit. In addition to Endosense, he currently serves on the boards of Acertys, ActoGeniX, Astex Therapeutics, Devgen, Pamgene, the Biotech Fund Flanders and FlandersBio. Former board seats include Innogenetics, Crucell, Avalon Pharmaceuticals, Hypnion (acquired by Eli Lilly) and CropDesign (acquired by BASF). Van Beneden has a degree in financial services from VLEKHO in Brussels.